Glioma

P=N/A, N=70, Active, not recruiting, Sunnybrook Health Sciences Centre | Recruiting --> Active, not recruiting

Furthermore, mathematical simulation analysis supported the notion that increased phosphorylation levels of BMAL1 and its subsequent nuclear localization could serve as a driving force for phase shifts in the circadian oscillatory system. In conclusion, our findings suggest that BMAL1-ISR acts as a key integrative "switching signal" linking diverse synchronization cues to molecular clock oscillations.

This trial met safety/feasibility primary end points with some preliminary signals of efficacy. ClinicalTrials.gov registration: NCT03652545 .

In conclusion, SOX10 negativity effectively excludes low-grade glioneuronal tumors/low-grade gliomas with oligodendrocyte-like features (except PLNTY) and non-neoplastic oligodendrocyte hyperplasia from oligodendrogliomas. SOX10 serves as a specific diagnostic marker, enhancing pathological diagnostic accuracy.

The interpretability of distance-based subcortical motor mapping is influenced by IDH1 mutation status, whereas continuous CUSA stimulation and ball-tip stimulation show comparable overall distance-threshold behavior. Distance-based scMEP thresholds are more reliable in IDH1-mutant tumors, whereas increased variability in IDH1-wildtype tumors likely reflects greater susceptibility to intraoperative brain shift and other biological factors, supporting a biologically informed, real-time electrophysiological approach in motor-eloquent tumor resections.

Doxorubicin (DOX) was efficiently encapsulated via temperature-controlled loading to obtain DOX@FTn-EGFRAfb with high protein recovery, pH-responsive drug release, and strong stability...In an orthotopic U87 glioma mouse model, DOX@FTn-EGFRAfb significantly inhibited tumor growth and prolonged survival without obvious systemic toxicity. This work presents a versatile protein-engineering strategy for dual-targeted glioblastoma drug delivery.

Across glioma subtypes, OCAv3 enabled integrated classification in most cases, particularly in oligodendroglioma and glioblastoma, by simultaneously assessing SVs and CNVs. Implementation in the prospective clinical cohort reduced required FISH studies by 90%, significantly shortened turnaround times, and decreased molecular testing costs.

Anti-GPNMB CAR-T cells showed potent anti-tumour activity, with long-term disease control in orthotopic patient-derived xenografts and syngeneic glioma models through concomitant depletion of GPNMB+ tumour and immunosuppressive myeloid populations. By collapsing tumour control and microenvironmental reprogramming, these findings provide a new strategy for antigen selection and targeting in heterogenous, myeloid-rich solid cancers.

IDH1-vac-induced T cell responses were detected in the inflamed brain lesion of an IDH1-vac-associated pseudoprogression, whereas no IDH1-vac-induced T cells were found in participants with early progressive disease. The favorable long-term outcome of the NOA16 cohort supports investigating IDH1-vac in persons with newly diagnosed grade 3 and 4 (World Health Organization classification 2021) IDH-mutant astrocytomas in a randomized phase 2 trial (ClinicalTrials.gov identifier: NCT02454634 ).

P2, N=30, Not yet recruiting, HighField Biopharmaceuticals Corporation

P=N/A, N=15, Active, not recruiting, NYU Langone Health | Recruiting --> Active, not recruiting

P1, N=19, Active, not recruiting, City of Hope Medical Center | Trial completion date: Jun 2026 --> May 2027 | Trial primary completion date: Jun 2026 --> May 2027